Publication
Title
Wilms' tumor gene 1 (WT1) - loaded dendritic cell immunotherapy in patients with uterine tumors : a phase I/II clinical trial
Author
Abstract
Aim: Treatment options are limited in uterine cancer, leading to a poor prognosis. Overexpression of Wilms' tumor gene 1 (WT1), the highest ranked tumor antigen, is attractive for immunotherapy. Patients and Methods: Six pre-treated patients with uterine cancer received four weekly vaccines of autologous dendritic cells (DCs) electroporated with WT1 mRNA. Safety, feasibility and immunogenicity were assessed. In cases of response, patients received monthly booster vaccines. Results: The technique was feasible. One patient had a local allergic reaction. Three out of four Human Leucocyte Antigen-A2 (HLA-A2)-positive patients showed an oncological response; an enrichment of WT1-specific T-cells was observed in two of them. Two HLA-A2-negative patients did not show an oncological or an immunological response. Conclusion: A first series of six patients with uterine cancer treated with WT1 mRNA-electroporated DCs is presented herein. Oncological and immunological responses were observed and are supportive for further research.
Language
English
Source (journal)
Anticancer research. - Athens
Publication
Athens : 2013
ISSN
0250-7005
Volume/pages
33:12(2013), p. 5495-5500
ISI
000328801900035
UAntwerpen
Faculty/Department
Research group
Publication type
Subject
Affiliation
Publications with a UAntwerp address
External links
Web of Science
Record
Identification
Creation 06.02.2014
Last edited 05.08.2017
To cite this reference